---
title: "Here’s How Much You Would Have Made Owning Royalty Pharma Stock In The Last 10 Years"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295983710.md"
description: "Royalty Pharma (NASDAQ: RPRX) has outperformed the market over the past decade, achieving an annualized return of 39.56%, which exceeds the market by 26.07%. With a current market capitalization of $26.09 billion and a stock price of $58.60, a hypothetical $100 investment made ten years ago would now be worth $2,790.48. The article highlights the significant impact of compounded returns on cash growth over time."
datetime: "2026-08-14T22:46:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295983710.md)
  - [en](https://longbridge.com/en/news/295983710.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295983710.md)
generator: "portal-rs"
---

# Here’s How Much You Would Have Made Owning Royalty Pharma Stock In The Last 10 Years

Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.56%. Currently, Royalty Pharma has a market capitalization of $26.09 billion.

**Buying $100 In RPRX:** If an investor had bought $100 of RPRX stock 10 years ago, it would be worth **$2,790.48** today based on a price of $58.60 for RPRX at the time of writing.

### Royalty Pharma’s Performance Over Last 10 Years

![comp_fig](https://imageproxy.pbkrs.com/https://cdn.benzinga.com/files/images/story/2026/08/14/5531a55e8c27af2c8c706c58a593dd74.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

Finally -- what’s the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.

*This article was generated by Benzinga's automated content engine and reviewed by an editor.*

### Related Stocks

- [RPRX.US](https://longbridge.com/en/quote/RPRX.US.md)

## Related News & Research

- [If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/296656460.md)
- [Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal?](https://longbridge.com/en/news/296647266.md)
- [Royalty Pharma EVP and Chairman of Partnering Christopher Hite sells 100,000 shares for $6 million](https://longbridge.com/en/news/296396564.md)
- [Royalty Pharma CFO Terrance P. Coyne sells USD 645,248 in common shares](https://longbridge.com/en/news/296146007.md)
- [Here’s How Much You Would Have Made Owning MKS Stock In The Last 10 Years](https://longbridge.com/en/news/296152109.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**